Key Players
Competitive Landscape
Four developer types compete in the Charcot-Marie-Tooth market: diversified pharmaceutical companies, oral small-molecule specialists, RNA platform developers and cell therapy companies.
Funding and technical investment have moved in two directions since 2025: orally administered mechanism-specific candidates and scalable potency testing for vectorized RNA interference. In March 2025, Augustine Therapeutics completed a USD 84.8 million Series A round to advance AGT-100216 into CMT clinical development. Armatus Bio introduced a scalable potency assay platform in May 2026 for vectorized RNA interference programs that include CMT1A. Investors and prospective partners now assess subtype precision alongside endpoint credibility and practical dosing across the long studies required for slowly progressive disease.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Augustine Therapeutics completed a USD 84.8 million Series A financing round in March 2025 for AGT-100216 clinical development. | Investors funded a candidate designed for chronic oral dosing across a disease without approved disease-modifying therapy. | Private financing is concentrating around mechanism-specific programs that can enter controlled human studies with measurable pharmacology. | Revenue depends on repeat oral dosing across long-duration treatment if later studies confirm durable functional improvement. |
| Actio Biosciences dosed the first Phase 1 participant in March 2025 for the oral TRPV4 inhibitor ABS-0871. | Specialist centers need genotype-confirmed candidates that address neurologic and respiratory features associated with TRPV4-positive CMT2C. | Clinical pipelines are separating broad CMT labels into genotype-defined programs with narrower enrollment criteria and endpoints. | A successful oral inhibitor could address neurologic and respiratory impairment within one genetically selected CMT2C population. |
| Armatus Bio introduced a scalable potency assay platform in May 2026 for vectorized RNA interference programs including CMT1A. | Gene-silencing developers need reproducible potency measurements so regulators can assess lot consistency and stability during development. | Preclinical competition increasingly includes manufacturing assays alongside vectors and therapeutic payload design during regulated translational development. | Assay licensing could support CMT1A programs that need reproducible potency evidence before clinical manufacturing begins. |
Novartis AG, NMD Pharma A/S, ENCell Co., Ltd., Vanda Pharmaceuticals Inc. and Oryzon Genomics, S.A. compete through clinical maturity and subtype focus beyond the financing and assay investments summarized above.
Source: Future Market Insights, Charcot-Marie-Tooth Market and Rare Neurological Disease Treatment Market Reports, 2026-2036.
Augustine Therapeutics and Actio Biosciences cover oral HDAC6 and TRPV4 inhibition across clinical-stage programs, while Armatus Bio adds vectorized RNA interference supported by CMT1A potency testing.
Who leads the Charcot-Marie-Tooth market?
No company leads through approved disease-modifying sales because CMT currently lacks an approved disease-modifying therapy. NMD Pharma and ENCell hold later-stage exact-market positions through Phase 2a programs in CMT1 or CMT2 populations.
Which developers have documented regulatory designations?
NMD Pharma received FDA orphan drug designation for NMD670 in Charcot-Marie-Tooth disease during January 2025. ENCell reported European Medicines Agency orphan medicinal product designation for EN001 in CMT1A during May 2026.
Which companies address genotype-defined CMT subtypes?
Novartis targets PMP22-duplicated CMT1A through EDK060, while Armatus Bio develops vectorized RNA interference for the same subtype. Vanda Pharmaceuticals addresses a single IGHMBP2 variant in CMT2S and Actio Biosciences targets TRPV4-positive CMT2C.
Which developers operate across North America and Europe?
NMD Pharma studied ignaseclant across sites in the United States and Europe, while Novartis recruits EDK060 participants through Canadian centers. Augustine Therapeutics develops AGT-100216 from Belgium and Oryzon operates from Spain with a United States presence.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Novartis AG | Canada study coverage | Phase 1 EDK060 siRNA program for genetically confirmed CMT1A with intravenous single-dose escalation in Canada. |
| NMD Pharma A/S | United States and Europe | Phase 2a oral ignaseclant program evaluated across 81 adults with genetically confirmed CMT1 or CMT2. |
| ENCell Co., Ltd. | South Korea | Phase 2a EN001 mesenchymal stem-cell program for CMT1A with clinical dosing at South Korean university hospitals. |
| Augustine Therapeutics NV | Belgium and Europe | Oral peripherally restricted HDAC6 inhibitor AGT-100216 in Phase 1 following USD 84.8 million financing. |
| Vanda Pharmaceuticals Inc. | United States | VCA-894A antisense oligonucleotide targets a single IGHMBP2 splice variant associated with genetically defined CMT2S disease. |
| Armatus Bio | United States | TVR110 vectorized RNA interference candidate for CMT1A uses a scalable product-potency assay supporting regulated development. |
| Actio Biosciences | United States | Once-daily oral TRPV4 inhibitor ABS-0871 entered Phase 1 development for genetically confirmed TRPV4-positive CMT2C patients. |
| Oryzon Genomics, S.A. | Spain and United States | Selective HDAC6 inhibitor ORY-4001 continues through IND-enabling studies for CMT and related neurological disorders across preclinical development. |
Research Methodology
The selected companies illustrate how CMT development is divided across clinical stages, molecular targets and therapeutic delivery models without implying a commercial ranking. Inclusion requires current evidence that a developer maintains a CMT candidate or an enabling platform directly supporting CMT development. Company announcements, clinical records, filings and regulatory designations establish program stage and documented market relevance. Geographic coverage reflects verified study locations or operating presence connected to each named development program. Clinical stage and subtype claims apply to the cited program rather than the wider corporate group. The 39.0% supportive therapy share applies to 2026 and remains an FMI estimate within the defined treatment-type taxonomy.
